Supreme to Attend Green Rush Financial Conference June 26, 2014


VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 25, 2014) - Supreme Pharmaceuticals Inc. (the "Company") (CSE:SL)(OTCBB:SPRWF) is pleased to announce that the Company will be attending the second Green Rush Financial Conference of 2014 in Toronto, Ontario, on Thursday June 26, 2014. The Company will be exhibiting at booth # 311 from the hours of 7:30 am until 6:00 pm.

In addition, senior management will be giving a corporate presentation at 3:35 pm where President and CEO, David Stadnyk, and Director of Operations, John Fowler, will be speaking.

Management at Supreme are looking forward to meeting shareholders and stakeholders in person, and providing information regarding the Company's recently acquired subsidiary holding a pre-build MMPR. Anyone interested is encouraged to come by.

Details:
http://www.greenrushfinancialconferences.com/s/toronto-events.asp?ReportID=652228&_Type=Toronto-GreenRush-Conference&_Title=SponsorsExhibitors
June 26th, 2014
7:30am - 6:00pm
Metro Toronto Convention Centre North

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the acquisition of an MMPR license in respect to its Southern Okanagan facility, the timing on competition of the MMPR License conditions for its Southern Ontario facility and the start of production. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and such factors as the Company failing to acquire final MMPR licenses and put the same into production. This news release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995.

Contact Information:

Supreme Pharmaceuticals Inc.
Investor Relations
(647) 340-6744
info@supremepharmaceuticals.com
www.supremepharmaceuticals.com